Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29163844 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL15057262 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL15056773 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL28731364 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL18561053 | 0.88 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL31420607 | 0.88 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL31420863 | 0.88 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL10215607 | 0.87 | CHRM2 (0.39) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL2542677 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL15270709 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | NR1H2 2065/4885CHRM2 1757/4885CHRM1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.